Company: SUPN
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001356576-25-000071
Chunk: 244

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 244
---
 the Company writes down the asset to its estimated fair value, and an impairment loss equal to the difference between the assets fair value and carrying value is recognized in the consolidated statement of earnings (loss) in the period at which such determination is made. The use of different assumptions could increase or decrease the estimated fair value of assets and could therefore affect any impairment measurement. There were no impairment charges for the three and nine months ended September 30, 2025. 

45

Results of Operations

Comparison of the Three and Nine Months ended Months Ended September 30, 2025 and 2024 

Revenues

Revenues consist primarily of net product sales of our commercial products in the U.S., supplemented by royalty and licensing revenues from our collaborative licensing arrangements. The following table provides information regarding our revenues during the three and nine months ended months ended September 30, 2025 (dollars in thousands):Three Months EndedSeptember 30,ChangeNine Months EndedSeptember 30,Change20252024AmountPercent20252024AmountPercentNet product salesQelbree$81,416 $62,359 $19,057 31%$223,708 $166,857 $56,851 34%GOCOVRI40,849 35,657 5,192 15%108,198 93,922 14,276 15%APOKYN10,387 19,867 (9,480)(48)%38,183 53,811 (15,628)(29)%Trokendi XR10,043 15,318 (5,275)(34)%34,037 48,393 (14,356)(30)%Oxtellar XR12,016 29,805 (17,789)(60)%33,851 86,265 (52,414)(61)%ONAPGO6,806 — 6,806 100 %8,410 — 8,410 100 %Other(1)7,025 7,296 (271)(4)%22,138 22,053 85 —%Total net product sales168,542 170,302 (1,760)(1)%468,525 471,301 (2,776)(1)%Collaboration revenue (ZURZUVAE)(2)20,164 — 20,164 100%20,164 — 20,164 100